Advertisement

Abdominal Imaging

, Volume 36, Issue 3, pp 282–289 | Cite as

Hepatocellular nodules in liver cirrhosis: MR evaluation

Invited Feature Section

Abstract

Liver cirrhosis is a major public health problem worldwide. Common causes of cirrhosis include hepatitis C virus, hepatitis B virus, alcohol consumption, and nonalcoholic steatohepatitis. Cirrhotic livers are characterized by advanced hepatic fibrosis and the development of hepatocellular nodules such as regenerative nodules, dysplastic or neoplastic nodules. Cirrhosis is the strongest predisposing factor for hepatocellular carcinoma (HCC). For example, viral hepatitis is the main risk factor for cirrhosis and is associated with the increased incidence (1%–4% per year) of HCC after development of cirrhosis. Currently, a variety of imaging modalities, including ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI), and positron-emission tomography (PET) are used in noninvasive evaluation of patients with chronic liver disease and suspected HCC. With technological development of MR scanners, MR imaging has emerged as an important imaging modality for assessing cirrhosis and its complications such as HCC. The recent advance in MR is the introduction of faster sequences which have allowed high-quality imaging of the entire liver with high intrinsic soft-tissue contrast, and also multiphasic dynamic MRI that is essential for the detection and characterization of HCC. In addition, functional MRI including diffusion-weighted MRI, MR elastography, and new MR contrast agent with dual function have been investigated for the clinical utility of detection and characterization of HCCs. In this article, we provide an overview of the state-of-the-art MR imaging techniques being used for noninvasive assessment of hepatocellular nodules including conventional dynamic imaging, liver-specific contrast-enhanced MR imaging, diffusion-weighted imaging, MR spectroscopy, and MR elastography.

Keywords

Hepatocellular carcinoma MRI Contrast agent Liver tumors Diffusion MR Elastography 

References

  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156PubMedCrossRefGoogle Scholar
  2. 2.
    MacSween RNM, Burt A, Portmann B (2002) Pathology of the liver, 4th edn. Churchill Livingstone: LondonGoogle Scholar
  3. 3.
    El Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750PubMedCrossRefGoogle Scholar
  4. 4.
    Hanna RF, Aguirre DA, Kased N, et al. (2008) Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. Radiographics 28:747–769PubMedCrossRefGoogle Scholar
  5. 5.
    Choi BI (2004) The current status of imaging diagnosis of hepatocellular carcinoma. Liver Transplant 10:S20–S25CrossRefGoogle Scholar
  6. 6.
    Willatt JM, Hussain HK, Adusumilli S, Marrero JA (2008) MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 247:311–330PubMedCrossRefGoogle Scholar
  7. 7.
    Coleman WB (2003) Mechanisms of human hepatocarcinogenesis. Curr Mol Med 3:573–588PubMedCrossRefGoogle Scholar
  8. 8.
    Shah TU, Semelka RC, Pamuklar E, et al. (2006) The risk of hepatocellular carcinoma in cirrhotic patients with small liver nodules on MRI. Am J Gastroeneterol 101:533–540CrossRefGoogle Scholar
  9. 9.
    Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Hepatology 42:1208–1236PubMedCrossRefGoogle Scholar
  10. 10.
    Zech CJ, Reiser MF, Herrmann KA (2009) Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis 27:114–124PubMedCrossRefGoogle Scholar
  11. 11.
    Bartolozzi C, Battaglia V, Bozzi E (2009) HCC diagnosis with liver-specific MRI-close to histopathology. Dig Dis 27:125–130PubMedCrossRefGoogle Scholar
  12. 12.
    Hayashi M, Matsui O, Ueda K, et al. (1999) Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. AJR 172:969–976PubMedGoogle Scholar
  13. 13.
    Choi BI, Lee JM (2010) Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: imaging diagnosis and staging of hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 4:369–373CrossRefGoogle Scholar
  14. 14.
    Lee DH, Kim SH, Lee JM, et al. (2009) Diagnostic performance of multidetector row computed tomography, superparamagnetic iron oxide-enhanced magnetic resonance imaging, and dual-contrast magnetic resonance imaging in predicting the appropriateness of a transplant recipient based on milan criteria: correlation with histopathological findings. Invest Radiol 44:311–321PubMedCrossRefGoogle Scholar
  15. 15.
    Kim SH, Choi D, Kim SH, et al. (2005) Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR 184:1069–1076PubMedGoogle Scholar
  16. 16.
    Kim YK, Kwak HS, Kim CS, et al. (2006) Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detecter row CT. Radiology 238:531–541PubMedCrossRefGoogle Scholar
  17. 17.
    Choi SH, Lee JM, Yu NC, et al. (2008) Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI. AJR 191:529–536PubMedCrossRefGoogle Scholar
  18. 18.
    Park HS, Lee JM, Kim SH, et al. (2009) Differentiation of well-differentiated hepatocellular carcinomas from other hepatocellular nodules in cirrhotic liver: value of SPIO-enhanced MR imaging at 3.0 Tesla. J Magn Reson Imaging 29:328–335PubMedCrossRefGoogle Scholar
  19. 19.
    Sun HY, Lee JM, Shin CI, et al. (2010) Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or = 2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 45(2):96–103PubMedCrossRefGoogle Scholar
  20. 20.
    Motosugi U, Ichikawa T, Sou H, et al. (2010) Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 256(1):151–158PubMedCrossRefGoogle Scholar
  21. 21.
    Ahn SS, Kim MJ, Lim JS, et al. (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 255(2):459–466PubMedCrossRefGoogle Scholar
  22. 22.
    Jung G, Breuer J, Poll LW, et al. (2006) Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol 47:15–23PubMedCrossRefGoogle Scholar
  23. 23.
    Bartolozzi C, Crocetti L, Lencioni R, et al. (2007) Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 17:2519–2530PubMedCrossRefGoogle Scholar
  24. 24.
    Hammerstingl R, Huppertz A, Breuer J, et al. (2008) Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesion. Eur Radiol 18:457–467PubMedCrossRefGoogle Scholar
  25. 25.
    Kim SH, Kim SH, Lee J, et al. (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR 192:1675–1681PubMedCrossRefGoogle Scholar
  26. 26.
    Kim JI, Lee JM, Choi JY, et al. (2008) The value of gadobenate dimeglumine-enhanced delayed-phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 43:202–210PubMedCrossRefGoogle Scholar
  27. 27.
    Tsuboyama T, Onishi H, Kim T, et al. (2010) Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging—correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 255(3):824–833PubMedCrossRefGoogle Scholar
  28. 28.
    Narita M, Hatano E, Arizono S, et al. (2009) Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 44(7):793–798PubMedCrossRefGoogle Scholar
  29. 29.
    Kele P, van der Jagt EJ (2010) Diffusion weighted imaging in the liver. World J Gastroenterol 16:1567–1576PubMedCrossRefGoogle Scholar
  30. 30.
    Taouli B, Ehman RL, Reeder SB (2009) Advanced MRI methods for assessment of chronic liver disease. AJR 193:14–27PubMedCrossRefGoogle Scholar
  31. 31.
    Bammer R (2003) Basic principles of diffusion-weighted imaging. Eur J Radiol 45:169–184PubMedCrossRefGoogle Scholar
  32. 32.
    Charles-Edwards EM, de Souza NM (2006) Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging 6:135–143PubMedCrossRefGoogle Scholar
  33. 33.
    Vandecaveye V, De Keyzer F, Verslype C, et al. (2009) Diffuseion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol 19:2456–2466PubMedCrossRefGoogle Scholar
  34. 34.
    Taouli B, Sandberg A, Stemmer A, et al. (2009) Diffusion-weighted imaging of the liver: comparison of navigator triggered and breathhold acquisitions. J Magn Reson Imaging 30:561–568PubMedCrossRefGoogle Scholar
  35. 35.
    Bruegel M, Holzapfel K, Gaa J, et al. (2008) Characterization of focal live rlesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol 18:477–485PubMedCrossRefGoogle Scholar
  36. 36.
    Miller FH, Hammond N, Siddiqi AJ (2010) Utility of diffusion-weighted MRI in distinguishing benign and malignant hepatic lesions. J Magn Reson Imaging 32(1):138–147PubMedCrossRefGoogle Scholar
  37. 37.
    Taouli B, Ko DM (2010) Diffusion-weighted MR imaging of the liver. Radiology 254:47–66PubMedCrossRefGoogle Scholar
  38. 38.
    Venkatesh SK, Yin M, Glockner JF, et al. (2008) MR elastography of liver tumors: preliminary results. AJR 190:1534–1540PubMedCrossRefGoogle Scholar
  39. 39.
    Mariappan YK, Glaser KJ, Ehman RL (2010) Magnetic resonance elastography: a review. Clin Anat 23:497–511PubMedCrossRefGoogle Scholar
  40. 40.
    Faria SC, Ganesan K, Mwangi I, et al. (2009) MR imaging of liver fibrosis: current state of the art. Radiographics 29(6):1615–1635 (Review)PubMedCrossRefGoogle Scholar
  41. 41.
    Yin M, Chen J, Glaser KJ, Talwalkar JA, Ehman RL (2009) Abdominal magnetic resonance elastography. Top Magn Reson Imaging 20(2):79–87PubMedCrossRefGoogle Scholar
  42. 42.
    Sijens PE (2009) Parametric exploration of the liver by magnetic resonance methods. Eur Radiol 19(11):2594–2607PubMedCrossRefGoogle Scholar
  43. 43.
    Soper R, Himmerlreich U, Painter D, et al. (2002) Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance spectroscopy and a statistical classification strategy. Pathology 34:417–422PubMedCrossRefGoogle Scholar
  44. 44.
    Irwan R, Edens MA, Sijens PE (2008) Assessment of the variations in fat content in normal liver using a fast quantification MR imaging method in comparison with results obtained by spectroscopic imaging. Eur Radiol 18:806–813PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of RadiologySeoul National University College of Medicine and Institute of Radiation MedicineSeoulKorea

Personalised recommendations